建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
Oneness has submitted medical device registration application of Bonvadis for wound care to the Saudi Food and Drug Authority (SFDA) in Kingdom of Saudi Arabia.
Oneness announces the information about the investor's conference of 2023 Q4.
Oneness Biotech Co., Ltd. receives an Indian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
News-Oneness is the first pharmaceutical company in Taiwan has been selected for inclusion in the Dow Jones Sustainability Index
Oneness Biotech Co., Ltd. receives a Brazilian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
A U.S. patent titled ”METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTS” has been granted.
Oneness Biotech Co., Ltd. receives a Japanese patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825.
Oneness announces the resolution of the Board of Directors on the Record Date of Capital Increase for the issuance of Restricted Employee Shares in 2023.
An European patent titled “USE OF FLAVONOID COMPOUND IN PREPARATION OF COMPOSITION FOR HEALING WOUND” has been granted.
Oneness Biotech Co., Ltd. receives a Hong Kong patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved as Class 1.1 natural new drug by National Medical Products Administration (NMPA) in China
The Company's 2023Q3 consolidated financial statements have been approved by the Board of Directors
Oneness has submitted medical device registration application of Bonvadis for wound care to the Thai Food and Drug Administration (Thai FDA) in Thailand.
The board of directors of the Company approved removal of the noncompete clause for managers.
The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?